Harry Crijns


Harry Crijns is professor and chair of Cardiology and board member of the Cardiovascular Research Institute Maastricht (CARIM) at Maastricht UMC+. He studied medicine at the University of Amsterdam and was trained in cardiology and electrophysiology in Groningen and Maastricht. He is a Fellow of the ESC and a past board member of the EHRA. He is also past Chair of the Netherlands Society of Cardiology. He served on several guidelines committees for the management of AF. Currently he is the chairman of the scientific advisory board of the Dutch Heart Foundation.

His primary research focus continues to be atrial fibrillation (AF). He founded the RACE trials in the Netherlands and led the Euro Heart Survey on AF (ESC). He has established his reputation by introducing innovative concepts for diagnosis and treatment of AF by showing that - quite contrary to longstanding beliefs - electrical management does not change prognosis. This revolutionised management of the arrhythmia worldwide with the effect that major interventions like electrical cardioversion, catheter ablation and antiarrhythmic drug therapy are applied in a much more personalized fashion.

Subsequently his group showed that rate control in AF can be individualized thereby removing the previously used strict heart rate targets from the international guidelines. He also performed the Euro Heart Survey on AF and made many contributions to the field of stroke management in AF, such as the construction of well-recognised AF specific risk stratification scores for AF progression (HATCH), ischemic stroke (CHA2DS2-VASc) and major bleeding (HAS-BLED). These scores have practically conquered the medical AF community and improved patient care whilst boosting new clinical research throughout the world.

His research group now focusses on recent-onset AF, hybrid AF ablation, upstream therapy and vascular mechanisms for AF progression and stroke in idiopathic atrial fibrillation. He is (co-)author on over 650 scientific articles, with 56,677 citations and Hirsch-index of 100.

Department of Cardiology
P. Debyelaan 25, 6229 HX Maastricht 
PO Box 5800, 6202 AZ Maastricht

  • 2022
    • Smits, E., Andreotti, F., Houben, E., Crijns, H. J. G. M., Haas, S., Spentzouris, G., Schink, T., Gini, R., Bartolini, C., Penning-van Beest, F., & Herings, R. (2022). Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. Drugs-Real World Outcomes, 9(2), 199-209. https://doi.org/10.1007/s40801-021-00289-w
    • Camm, A. J., Naccarelli, G. V., Mittal, S., Crijns, H. J. G. M., Hohnloser, S. H., Ma, C-S., Natale, A., Turakhia, M. P., & Kirchhof, P. (2022). The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 79(19), 1932-1948. https://doi.org/10.1016/j.jacc.2022.03.337
    • Hermans, A. N. L., Gawalko, M., Dohmen, L., van der Velden, R. M. J., Betz, K., Duncker, D., Verhaert, D. V. M., Heidbuchel, H., Svennberg, E., Neubeck, L., Eckstein, J., Lane, D. A., Lip, G. Y. H., Crijns, H. J. G. M., Sanders, P., Hendriks, J. M., Pluymaekers, N. A. H. A., & Linz, D. (2022). Mobile health solutions for atrial fibrillation detection and management: a systematic review. Clinical research in cardiology, 111(5), 479-491. https://doi.org/10.1007/s00392-021-01941-9
    • Metzner, A., Suling, A., Brandes, A., Breithardt, G., Camm, A. J., Crijns, H. J. G. M., Eckardt, L., Elvan, A., Goette, A., Haegeli, L. M., Heidbuchel, H., Kautzner, J., Kuck, K-H., Mont, L., Ng, A. A., Szumowski, L., Themistoclakis, S., van Gelder, I. C., Vardas, P., ... Kirchhof, P. (2022). Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. EP Europace, 24(4), 552-564. https://doi.org/10.1093/europace/euab200
    • Willems, S., Borof, K., Brandes, A., Breithardt, G., Camm, A. J., Crijns, H. J. G. M., Eckardt, L., Gessler, N., Goette, A., Haegeli, L. M., Heidbuchel, H., Kautzner, J., Ng, G. A., Schnabel, R. B., Suling, A., Szumowski, L., Themistoclakis, S., Vardas, P., van Gelder, I. C., ... Kirchhof, P. (2022). Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. European Heart Journal, 43(12), 1219-1230. https://doi.org/10.1093/eurheartj/ehab593
    • Crijns, H. J. G. M., Sanders, P., Albert, C. M., & Lambiase, P. D. (2022). The year in cardiovascular medicine 2021: arrhythmias. European Heart Journal, 43(12), 1191-1197. https://doi.org/10.1093/eurheartj/ehac007
    • Koldenhof, T., Wijtvliet, P. E. P. J., Pluymaekers, N. A. H. A., Rienstra, M., Folkeringa, R. J., Bronzwaer, P., Elvan, A., Elders, J., Tukkie, R., Luermans, J. G. L. M., van Kuijk, S. M. J., Tijssen, J. G. P., van Gelder, I. C., Crijns, H. J. G. M., & Tieleman, R. G. (2022). Rate control drugs differ in the prevention of progression of atrial fibrillation. EP Europace, 24(3), 384-389. https://doi.org/10.1093/europace/euab191
    • Luyten, P., Heuts, S., Cheriex, E., Olsthoorn, J. R., Crijns, H. J. G. M., Winkens, B., Roos-Hesselink, J. W., Nia, P. S., & Schalla, S. (2022). Mitral prolapsing volume is associated with increased cardiac dimensions in patients with mitral annular disjunction. Netherlands Heart Journal, 30(3), 131-139. https://doi.org/10.1007/s12471-021-01575-6
    • De With, R. R., Artola Arita, V., Nguyen, B-O., Linz, D., Ten Cate, H., Spronk, H., Schotten, U., van Zonneveld, A. J., Erküner, Ö., Bayón, M. A., Schmidt, A. S., Luermans, J. G. L. M., Crijns, H. J. G. M., Van Gelder, I. C., & Rienstra, M. (2022). Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies. EP Europace, 24(2), 193-201. https://doi.org/10.1093/europace/euab179
    • Thind, M., Zareba, W., Atar, D., Crijns, H. J. G. M., Zhu, J., Pak, H. N., Reiffel, J., Ludwigs, U., Wieloch, M., Stewart, J., & Kowey, P. (2022). Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials. Clinical Cardiology, 45(1), 101-109. https://doi.org/10.1002/clc.23765